Literature DB >> 2564763

Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Flurazepam, temazepam, and triazolam.

D J Greenblatt1, J S Harmatz, N Engelhardt, R I Shader.   

Abstract

Healthy adult volunteers (n = 52) received single oral doses of flurazepam hydrochloride (15 mg), temazepam (15 mg), triazolam (0.25 mg), or placebo in a parallel, double-blind study. Sedative effects were greatest with triazolam, followed next by temazepam; peak effects closely coincided with peak plasma concentrations. Differential recovery from sedation corresponded in part to differences in mean elimination halflife, although sedative effects returned to baseline before plasma drug concentrations became undetectable. Sedation following flurazepam administration was less intense than with triazolam and temazepam. When tested at three hours after dosing, none of the active treatments impaired learning of a 16-item word list. However, at 24 hours, triazolam recipients could not recall a significant fraction of what was learned. Thus, dynamic differences among three benzodiazepine hypnotics may be partly explained by kinetic differences, as well as, we should caution, by possible "clinical inequivalence" in dosage.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564763     DOI: 10.1001/archpsyc.1989.01810040032006

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  15 in total

1.  The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state.

Authors:  J M Scavone; D J Greenblatt; J E Goddard; H Friedman; J S Harmatz; R I Shader
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  The efficacy and memory effects of oral triazolam premedication in highly anxious dental patients.

Authors:  P Milgrom; F C Quarnstrom; A Longley; E Libed
Journal:  Anesth Prog       Date:  1994

Review 3.  A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs.

Authors:  Cara Tannenbaum; Amélie Paquette; Sarah Hilmer; Jayna Holroyd-Leduc; Ryan Carnahan
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

4.  Characterization of cognitive dysfunction in Sjögren's syndrome patients.

Authors:  Lynn C Epstein; Gina Masse; Jerold S Harmatz; Tammy M Scott; Athena S Papas; David J Greenblatt
Journal:  Clin Rheumatol       Date:  2013-12-15       Impact factor: 2.980

5.  A comparison of the acute behavioral effects of triazolam and temazepam in normal volunteers.

Authors:  C R Rush; S T Higgins; J R Hughes; W K Bickel
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance.

Authors:  A B Dollins; I V Zhdanova; R J Wurtman; H J Lynch; M H Deng
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

Review 7.  Psychiatric complications in the critically ill cardiac patient.

Authors:  K M Sanders; E H Cassem
Journal:  Tex Heart Inst J       Date:  1993

Review 8.  Pharmacokinetic-pharmacodynamic relationships for benzodiazepines.

Authors:  B E Laurijssens; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

Review 9.  The use of microcomputer-based psychomotor tests for the evaluation of benzodiazepine effects on human performance: a review with emphasis on temazepam.

Authors:  G W Kunsman; J E Manno; B R Manno; C M Kunsman; M A Przekop
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

Review 10.  An assessment of short-acting hypnotics.

Authors:  W B Mendelson; B Jain
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.